Research programme: protein secretion therapeutics - Kezar Life Sciences
Latest Information Update: 15 Jul 2015
At a glance
- Originator Kezar Life Sciences
- Class Small molecules
- Mechanism of Action Protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer
Most Recent Events
- 16 Jun 2015 Early research in Cancer in USA (unspecified route)
- 16 Jun 2015 Early research in Autoimmune disorders in USA (unspecified route)